Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

Genes Chromosomes and Cancer

Volumn 47, Issue 10, 2008, Pages 853-859

  Agaram, Narasimhan P ^a   Wong, Grace C ^a   Guo, Tianhua ^a   Maki, Robert G ^a   Singer, Samuel ^a   DeMatteo, Ronald P ^a   Besmer, Peter ^a   Antonescu, Cristina R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IMATINIB;

ADOLESCENT; ADULT; ARTICLE; BRAF GENE; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NRAS GENE; PRIORITY JOURNAL; SMALL INTESTINE TUMOR; WILD TYPE;

ADULT; AGED; CHILD; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENES, RAS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 50249152932     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20589     Document Type: Article

References (29)

1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR. 2007. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13:170-181.
2. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan MF, Ladanyi M, DeMatteo RP, Besnier P. 2003. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9:3329-3337.
3. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. 2005. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182-41190.
4. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR. 2007. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257-264.
5. Bonneau D, Longy M. 2000. Mutations of the human PTEN gene. Hum Mutat 16:109-122.
6. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn FJ, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000.
7. Cruz F, III, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL. 2003. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63:5761-5766.
8. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147.
9. Curtin JA, Busam K, Pinkel D, Bastian BC. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346.
10. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M. 2004. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23:5968-5977.
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
12. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT. 2004. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response ro imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689-695.
13. Demetri GD, von Mehren M, Blanke CD, Van den Abbeelc AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal srromal tumors. N Engl J Med 347:472-480.
14. Gordon A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D. 2003. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63:3955-3957.
15. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR. 2007. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13:4874-4881.
16. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. 2007. The RTK/RAS/BRAF7PI3K pathways in melanoma: Biology, small molecule inhibitors, and potential applications. Semin Oncol 34:546-554.
17. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. 2003a. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349.
18. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. 2003b. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710.
19. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. 2006. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774.
20. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580.
21. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A. 2007. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470; discussion 470-471.
22. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. 2008. BRAF(E600) in benign and malignant human tumours. Oncogene. 27:877-895.
23. Minoo P, Mover MP, Jass JR. 2007. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 212:124-133.
24. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. 2005. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47:41-47.
25. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR, Besmer P. 2006. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 103:12843-12848.
26. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. 2001. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121.
27. Sharp S, Workman P. 2006. Inhibitors of the HSP90 molecular chaperone: Current status. Adv Cancer Res 95:323-348.
28. Solit DB, Garrawav LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. 2006. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362.
29. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. 2005. Human malignant melanoma: Detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36:486-493.